Nanobiotix reports 51M shares outstanding Oct. 31

Available on EDGAR 11/12/2026 - 04:15 PM EST Accepted by SEC EDGAR 11/12/2026 - 04:15 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Nanobiotix S.A. (NBTX) reported 50,968,893 shares outstanding as of October 31, 2026, alongside 54,726,179 theoretical voting rights and 54,704,061 exercisable voting rights.

The theoretical total includes shares with voting rights that are suspended; the exercisable total excludes shares held in treasury by the company.

Key Figures

Shares outstanding: 50,968,893 shares Theoretical voting rights: 54,726,179 voting rights Exercisable voting rights: 54,704,061 voting rights

3 metrics

Shares outstanding 50,968,893 shares As of October 31, 2026

Theoretical voting rights 54,726,179 voting rights As of October 31, 2026; includes voting rights attached to shares for which voting rights are suspended

Exercisable voting rights 54,704,061 voting rights As of October 31, 2026; excludes shares held in treasury by the company

Key Terms

theoretical (or “gross”) voting rights, exercisable at a shareholders’ meeting (or “net”) voting rights

2 terms

theoretical (or “gross”) voting rights regulatory

"The total number of theoretical (or “gross”) voting rights"

exercisable at a shareholders’ meeting (or “net”) voting rights regulatory

"The total number of exercisable at a shareholders’ meeting (or “net”) voting rights"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares and voting rights did NBTX report as of October 31, 2026?

Nanobiotix S.A. reported 50,968,893 shares outstanding, 54,726,179 theoretical voting rights, and 54,704,061 exercisable voting rights as of October 31, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2026

Commission File Number: 001-39777

Nanobiotix S.A.
(Translation of registrant's name into English)

60 Rue de Wattignies 75012 Paris, France
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

On November 12, 2026, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

(c) Exhibit 99.1. Press release dated November 12, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		Nanobiotix S.A.
		(Registrant)
Date: November 12, 2026		/s/ Brandon Owens
		Brandon Owens
		Vice President, Strategic Marketing and Corporate Communications

EXHIBIT 99.1

Voting Rights and Shares Capital of the Company

In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)

PARIS, Nov. 12, 2026 (GLOBE NEWSWIRE) --
Market: Euronext Paris / Nasdaq
Euronext Compartment: B
ISIN code: FR0011341205
Nasdaq: NBTX
Bloomberg: NANO:FP
Reuters: NANO.PA
Website: www.nanobiotix.com

Date	Number of Shares Outstanding	Total number of voting rights
		Total voting rights, theoretical1	Total voting rights, exercisable2
October 31, 2026	50,968,893	54,726,179	54,704,061

About NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has a subsidiary in Cambridge, Massachusetts (United States).

Nanobiotix is the owner of more than 30 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.

For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.

_________________________________

_{¹ The total number of theoretical (or “gross”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.}

_{² The total number of exercisable at a shareholders’ meeting (or “net”) voting rights is calculated without taking into account shares for which voting rights have been suspended as shares held in treasury by the Company. It is released in order to ensure that the public is properly informed.}

Contacts

Nanobiotix
Communications Department Brandon Owens VP, Communications +1 (617) 852-4835 contact@nanobiotix.com	Investor Relations Department Joanne Choi VP, Investor Relations (US) +1 (713) 609-3150 Ricky Bhajun Director, Investor Relations (EU) investors@nanobiotix.com
Media Relations
France – HARDY Caroline Hardy +33 06 70 33 49 50 carolinehardy@outlook.fr	Global – uncapped Becky Lauer +1 (646) 286-0057 uncappednanobiotix@uncappedcommunications.com

Attachments

• 20261112-Nanobiotix-PR_Voting_Rights_oct_2026 (https://ml.globenewswire.com/Resource/Download/381e0a63-40ff-4bce-993d-552bab7678b6)

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 PRESS RELEASE 7.6 KB